Clinical Trial Update: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating risdiplam in Type 2 and 3 Spinal Muscular Atrophy completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Risdiplam (risdiplam)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Muscular Atrophy, Spinal | Phase 2 | Status: COMPLETED | Results posted: 2021-06-15